Connect with us

Business

Cannabis producer Canopy’s subsidiary BioSteel enters ‘hibernation’ ahead of planned sale

Published

on

Struggling Canadian cannabis producer Canopy Growth Corp. is ceasing funding of its BioSteel subsidiary and plans to conduct a court-supervised sale of the brand and its property, the Ontario-based company said Thursday.

BioSteel, a popular sports nutrition and hydration brand, obtained an initial order for creditor protection under the Companies’ Creditors Arrangement Act (CCAA) from a Canadian court, according to a Canopy news release.

“(BioSteel) is insolvent,” according to a factum filed in the Ontario Superior Court of Justice. “It does not have adequate liquidity to operate its business in the ordinary course. Canopy and its affiliates are no longer willing to fund (BioSteel’s) operating costs.”

Canopy said the planned sale is part of its transformation plan, and the sports-beverage company does not align with the producer’s pivot to a marijuana-centric strategy.

“As while BioSteel’s business has shown significant year-over-year revenue growth, and we believe the brand remains an attractive asset, it does not align with Canopy Growth’s cannabis focused asset-light strategy,” Canopy CEO David Klein said in a statement.

“We have repeatedly demonstrated that we will take decisive action to enhance our profitability and ensure we are focused and positioned to be a leader in the North American cannabis sector.”

Canopy, which has not yet recorded a profit, has lost almost 6 billion Canadian dollars ($4.7 billion) since its inception.

As part of the transformation plan, Canopy in August sold its flagship facility in Smiths Falls, Ontario, back to its original owner, chocolate maker Hershey Canada, for CA$53 million.

Entering CCAA proceedings allows BioSteel to conserve cash and effectively puts the business “into hibernation to preserve its assets,” Canopy said in its announcement.

Canopy – which directly owns 90%-plus of BioSteel’s equity interests – and an affiliate have collectively advanced more than CA$366 million to BioSteel, court documents show.

BioSteel remains “significantly” cash-flow negative and had required continued support from Canopy in the estimated amount of CA$15 million per month, per the court documents.

In the fiscal year 2023, covering April 2022 through March 2023, BioSteel generated CA$69.6 million in sales, more than double the previous year’s total of CA$34.6 million.

However, the cost of goods sold for the BioSteel segment outran the brisk sales growth, coming in at CA$110.3 million in the same period, for a deficit of CA$40.6 million.

Court-supervised sale

BioSteel and Canopy started looking for or a buyer or additional investment for BioSteel beginning in late 2022, with the help of Goldman Sachs & Co., according to the court documents.

But that process returned no actionable bids, despite Goldman engaging with 24 potential buyers.

Canopy then formed a special committee and hired financial adviser Greenhill & Co. Canada to explore “strategic alternatives,” which included refocusing its sale efforts.

Because of BioSteel’s “rapidly deteriorating liquidity performance and based on feedback from Canopy regarding its diminishing willingness to provide financial and operational support” for the business, the committee set a deadline of Sept. 5, 2023, to receive proposals from interested parties, the court documents outlined.

Multiple parties expressed interest, but none were satisfactory.

So, on Sept. 13, Canopy informed BioSteel it did not intend to bankroll the business any longer and “demanded” repayment under the companies’ secured financing facility.

BioSteel currently owes roughly CA$366 million plus interest under its loan agreement and is unable to meet the obligations, records show.

The company also owes Canopy and its affiliates approximately CA$4.6 million on an unsecured basis.

Other unsecured debts amount to CA$40.4 million.

BioSteel intends to use the CCAA process to find a buyer “as efficiently as possible,” the court documents say.

Canopy said BioSteel will be responsible for the sale process under the supervision of the CCAA court.

“BioSteel intends to use this process to build on the work it undertook prior to the filing to identify a purchaser on an efficient basis,” according to Canopy’s release.

If approved by the CCAA court, the SISP will be administered by BioSteel with the assistance of Greenhill & Co. Canada and under the oversight of the monitor, KSV Restructuring.

Misstated revenue

In May 2023, Canopy said it uncovered “material misstatements” related to sales of its BioSteel business unit that were incorrectly accounted for.

The company said it initiated an internal review, under the oversight of the Audit Committee, and identified misstatements, primarily overstatements, related to the sports-beverage company’s sales.

Canopy restated its financial statements as a result of the review.

“All individuals implicated in the revenue misstatements are no longer involved with BioSteel – other than certain individuals in their capacities as minority shareholders – and an independent director was later added to the board of directors of each of the BioSteel Entities,” the court documents said.

Canopy said in August that BioSteel continued to be the subject of an investigation by the U.S. Securities and Exchange Commission.

The Ontario Securities Commission (OSC), the regulatory agency that administers and enforces securities rules, is conducting an “informal inquiry.”

No updates on those inquiries were shared.

In the court documents, Canopy did disclose that the sales process for BioSteel stalled earlier this year because of concerns identified regarding its financial reporting.

“The decision to seek creditor protection was made after careful evaluation of BioSteel’s financial situation and all available alternatives following consultation with its legal and financial advisors and a determination that a court supervised sale process is in the best interests of BioSteel and its stakeholders,” Canopy said in its release.

The initial order provides for a stay of proceedings in favor of BioSteel and its two American affiliates, BioSteel Sports Nutrition USA and BioSteel Manufacturing.

BioSteel’s board of directors will remain in place, the release noted.

BioSteel plans to fund the CCAA process from cash on hand and does not expect to require additional financing during the sale process.

The company leases a fully utilized facility in Verona, Virginia, that employed 90 of the company’s roughly 190 full-time employees as of August.

Shares of Smiths Falls-headquartered Canopy are traded on Toronto Stock Exchange and Nasdaq.

Source: https://mjbizdaily.com/canopy-subsidiary-biosteel-enters-hibernation-ahead-of-planned-sale/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News